3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
7
Brain Neoplasms
2
Stomach Neoplasms
1
Neoplasm Metastasis
1
HER2-positive Metastatic Breast Cancer
1
Colorectal Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Trastuzumab
2
tucatinib
1
tipifarnib
1
pembrolizumab
1
glutathione pegylated liposomal doxorubicin
1
elacestrant
1
abemaciclib
1
Temozolomide
1
Rituximab
1
RAD1901
1
Cancer Vaccines
1
Bevacizumab
1
Adjuvants, Immunologic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Central Nervous System Diseases
×
tucatinib
×
Clear all
NCT04512261
2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2
Withdrawn